The estimated Net Worth of Seth V Hetherington is at least 0$ dollars as of 9 November 2016. Seth Hetherington owns over 5,000 units of Genocea Biosciences Inc stock worth over 0$ and over the last 10 years Seth sold GNCA stock worth over 0$.
Seth has made over 4 trades of the Genocea Biosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Seth exercised 5,000 units of GNCA stock worth 10,100$ on 9 November 2016.
The largest trade Seth's ever made was exercising 11,000 units of Genocea Biosciences Inc stock on 18 August 2014 worth over 22,220$. On average, Seth trades about 3,714 units every 116 days since 2014. As of 9 November 2016 Seth still owns at least 26,000 units of Genocea Biosciences Inc stock.
You can see the complete history of Seth Hetherington stock trades at the bottom of the page.
Seth's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over 9,875,933$ worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth 259,728,894$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of 0$. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth 81$.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: